Market revenue in 2023 | USD 26,900.0 million |
Market revenue in 2030 | USD 43,875.7 million |
Growth rate | 7.2% (CAGR from 2023 to 2030) |
Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
Fastest growing segment | Antibody Drug Conjugate (ADC |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC |
Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.
Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 39.79% in 2023. Horizon Databook has segmented the Europe active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc covering the revenue growth of each sub-segment from 2018 to 2030.
Europe’s market held the third-largest share of 16.1% in 2020. It is one of the leading regions with advanced technologies and well-established infrastructure, resulting in improved healthcare facilities & patient care. Regulatory framework in the EU is expected to be subjected to major changes, which may affect market access or entry.
The market is expected to grow lucratively in this region due to stringent regulatory policies. To import active substances in Europe, the APIs should be manufactured in compliance with Good Manufacturing Practices (GMP), at least equivalent to the EU GMPs.
Presence of established market players, coupled with superior manufacturing capabilities, is anticipated to drive the market over the forecast period. Furthermore, increasing investments by multinational companies is anticipated to boost the market.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Europe active pharmaceutical ingredient cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account